|
|
Vaccine Detail
|
neoantigen synthetic long peptide vaccine |
| Vaccine Information |
- Vaccine Name: neoantigen synthetic long peptide vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: neoantigen (NCT05111353; NCT02510950), tumor-specific mutant antigens (TSMAs) (NCIT_C150471)
- Immunization Route: Intramuscular injection (i.m.)
- Description: This is a personalized peptide vaccine consisting of synthetic long peptides (SLPs), ranging from 20-35 amino acids in size, that are derived from two or more of the patient's tumor-specific mutant antigens (TSMAs), with potential immunostimulatory and antitumor activities. SLP vaccine may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL)-mediated immune response against the TSMAs expressed by the tumor cells. (NCIT_C150471) This vaccine is a optimized neoantigen synthetic long peptide (SLP) vaccines for pancreatic cancer patients following neoadjuvant chemotherapy. The neoantigen SLP vaccines will incorporate prioritized neoantigens and will be co-administered with poly-ICLC. (NCT05111353) It can be used in combination with chemoradiation with temozolomide for patients with newly diagnosed glioblastoma. (NCT02510950)
|
| Host Response |
|
|
| References |
NCIT_C150471: Personalized Synthetic Long Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C150471]
NCT02510950: Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma [https://clinicaltrials.gov/study/NCT02510950]
NCT05111353: Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery [https://clinicaltrials.gov/study/NCT05111353]
|
|
